 | Up a level |
Journal Article
Goldschmidt, H., Lokhorst, H. M., Mai, E. K., van der Holt, B., Blau, I. W., Zweegman, S., Weisel, K. C., Vellenga, E., Pfreundschuh, M., Kersten, M. J., Scheid, C., Croockewit, S., Raymakers, R., Hose, D., Potamianou, A., Jauch, A., Hillengass, J., Stevens-Kroef, M., Raab, M. S., Broijl, A., Lindemann, H. W., Bos, G. M. J., Brossart, P., Kooy, M. van Marwijk, Ypma, P., Duehrsen, U., Schaafsma, R. M., Bertsch, U., Hielscher, T., Jarari, Le, Salwender, H. J. and Sonneveld, P. (2018). Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMGHD-4 trial. Leukemia, 32 (2). S. 383 - 391. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Hoster, E., Geisler, C. H., Doorduijn, J., van der Holt, B., Walewski, J., Bloehdorn, J., Ribrag, V., Salles, G., Hallek, M., Pott, C., Szymczyk, M., Kolstad, A., Laurell, A., Raty, R., Jerkeman, M., van't Veer, M., Kluin-Nelemans, J. C., Klapper, W., Unterhalt, M., Dreyling, M. and Hermine, O. (2016). Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials. Leukemia, 30 (6). S. 1428 - 1431. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551